Drugs / QBS10072S
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04430842 | Jul 2020 → Sep 2022 | astrocytoma (excluding glioblastoma), breast cancer, cervical cancer, cholangiocarcinoma +15 | Quadriga Biosciences, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06810804 | Apr 2025 → Aug 2026 overdue | breast cancer | Nantong Bencao Quadriga Medical Technology Co. Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05305365 | Aug 2022 → Jun 2025 overdue | breast cancer, lung cancer, metastatic malignant neoplasm in the brain, neoplastic meningitis | Stanford University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02977780 | Feb 2017 → Feb 2028 expected | glioblastoma | Patrick Wen, MD | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QBS10072S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04430842 ↗ |
| Known as | NBQ72S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06810804 ↗ |
| Known as | QBS72S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05305365 ↗ |
| Route | Intravenous | “Intravenous administration of QBS10072S once every 4 weeks starting at 3mg/m2 and increasing dose levels in subsequent cohorts.” NCT04430842 ↗ |